<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Olson AP</submitter><funding>Office of Isotope Research and Development and Production</funding><funding>Workforce Development for Teachers and Scientists</funding><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><funding>National Institutes of Health</funding><funding>Office of Isotope R and D and Production</funding><funding>NIH HHS</funding><pagination>e202423878</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12536330</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>64(15)</volume><pubmed_abstract>Antimony-119 (&lt;sup>119&lt;/sup>Sb) is one of the most attractive Auger-electron emitters identified to date, but it remains practically unexplored for targeted radiotherapy because no chelators have been identified to stably bind this metalloid in vivo. In a departure from current studies focused on chelator development for Sb(III), we explore the chelation chemistry of Sb(V) using the tris-catecholate ligand TREN-CAM. Through a combination of radiolabeling, spectroscopic, solid-state, and computational studies, the radiochemistry and structural chemistry of TREN-CAM with &lt;sup>1XX/nat&lt;/sup>Sb(V) were established. The resulting [&lt;sup>1XX&lt;/sup>Sb]Sb-TREN-CAM complex remained intact for several days in human serum, signifying high stability under biological conditions. Finally, the first in vivo</pubmed_abstract><journal>Angewandte Chemie (International ed. in English)</journal><pubmed_title>Towards the Stable Chelation of Radioantimony(V) for Targeted Auger Theranostics.</pubmed_title><pmcid>PMC12536330</pmcid><funding_grant_id>F31 CA239617</funding_grant_id><funding_grant_id>F31CA239617</funding_grant_id><funding_grant_id>P01CA250972</funding_grant_id><funding_grant_id>P01 CA250972</funding_grant_id><pubmed_authors>Ivanov AS</pubmed_authors><pubmed_authors>Dierolf MA</pubmed_authors><pubmed_authors>Driscoll DM</pubmed_authors><pubmed_authors>Kertesz V</pubmed_authors><pubmed_authors>Verich F</pubmed_authors><pubmed_authors>Schrage BR</pubmed_authors><pubmed_authors>Becker KV</pubmed_authors><pubmed_authors>Fletcher LS</pubmed_authors><pubmed_authors>Boros E</pubmed_authors><pubmed_authors>Olson AP</pubmed_authors><pubmed_authors>Engle JW</pubmed_authors><pubmed_authors>White FD</pubmed_authors><pubmed_authors>Girish N</pubmed_authors><pubmed_authors>Thiele NA</pubmed_authors><pubmed_authors>Islam MF</pubmed_authors><pubmed_authors>Aluicio-Sarduy E</pubmed_authors><pubmed_authors>Simms ME</pubmed_authors></additional><is_claimable>false</is_claimable><name>Towards the Stable Chelation of Radioantimony(V) for Targeted Auger Theranostics.</name><description>Antimony-119 (&lt;sup>119&lt;/sup>Sb) is one of the most attractive Auger-electron emitters identified to date, but it remains practically unexplored for targeted radiotherapy because no chelators have been identified to stably bind this metalloid in vivo. In a departure from current studies focused on chelator development for Sb(III), we explore the chelation chemistry of Sb(V) using the tris-catecholate ligand TREN-CAM. Through a combination of radiolabeling, spectroscopic, solid-state, and computational studies, the radiochemistry and structural chemistry of TREN-CAM with &lt;sup>1XX/nat&lt;/sup>Sb(V) were established. The resulting [&lt;sup>1XX&lt;/sup>Sb]Sb-TREN-CAM complex remained intact for several days in human serum, signifying high stability under biological conditions. Finally, the first in vivo</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Apr</publication><modification>2026-06-04T14:14:44.863Z</modification><creation>2026-05-10T03:11:33.569Z</creation></dates><accession>S-EPMC12536330</accession><cross_references><pubmed>39878457</pubmed><doi>10.1002/anie.202423878</doi></cross_references></HashMap>